Literature DB >> 12096348

MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site.

Diana J Slater1, Eva Hilgenfeld, Eric F Rappaport, Narayan Shah, Rita G Meek, Wendy Reed Williams, Brian D Lovett, Neil Osheroff, Reshma S Autar, Thomas Ried, Carolyn A Felix.   

Abstract

We examined the MLL translocation in two cases of infant AML with X chromosome disruption. The G-banded karyotype in the first case suggested t(X;3)(q22;p21)ins(X;11)(q22;q13q25). Southern blot analysis showed one MLL rearrangement. Panhandle PCR approaches were used to identify the MLL fusion transcript and MLL genomic breakpoint junction. SEPTIN6 from chromosome band Xq24 was the partner gene of MLL. MLL exon 7 was joined in-frame to SEPTIN6 exon 2 in the fusion transcript. The MLL genomic breakpoint was in intron 7; the SEPTIN6 genomic breakpoint was in intron 1. Spectral karyotyping revealed a complex rearrangement disrupting band 11q23. FISH with a probe for MLL confirmed MLL involvement and showed that the MLL-SEPTIN6 junction was on the der(X). The MLL genomic breakpoint was a functional DNA topoisomerase II cleavage site in an in vitro assay. In the second case, the karyotype revealed t(X;11)(q22;q23). Southern blot analysis showed two MLL rearrangements. cDNA panhandle PCR detected a transcript fusing MLL exon 8 in-frame to SEPTIN6 exon 2. MLL and SEPTIN6 are vulnerable to damage to form recurrent translocations in infant AML. Identification of SEPTIN6 and the SEPTIN family members hCDCrel and MSF as partner genes of MLL suggests a common pathway to leukaemogenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096348     DOI: 10.1038/sj.onc.1205572

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

Review 1.  Roles of a trithorax group gene, MLL, in hematopoiesis.

Authors:  Ryoichi Ono; Tetsuya Nosaka; Yasuhide Hayashi
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

2.  Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.

Authors:  Jennifer S Dickey; Neil Osheroff
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

3.  Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis.

Authors:  Ryoichi Ono; Hideaki Nakajima; Katsutoshi Ozaki; Hidetoshi Kumagai; Toshiyuki Kawashima; Tomohiko Taki; Toshio Kitamura; Yasuhide Hayashi; Tetsuya Nosaka
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

4.  Hematopoietic gene expression profile in zebrafish kidney marrow.

Authors:  Huai-Dong Song; Xiao-Jian Sun; Min Deng; Guo-Wei Zhang; Yi Zhou; Xin-Yan Wu; Yan Sheng; Yi Chen; Zheng Ruan; Chun-Lei Jiang; Hui-Yong Fan; Leonard I Zon; John P Kanki; Ting Xi Liu; A Thomas Look; Zhu Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-01       Impact factor: 11.205

5.  Congenital X-linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6.

Authors:  Raffaele Renella; Katelyn Gagne; Ellen Beauchamp; Jonathan Fogel; Aleksej Perlov; Mireia Sola; Thorsten Schlaeger; Inga Hofmann; Akiko Shimamura; Benjamin L Ebert; Klaus Schmitz-Abe; Kyriacos Markianos; Kristi Murphy; Liang Sun; Shira Rockowitz; Piotr Sliz; Dean R Campagna; Timothy A Springer; Christopher Bahl; Suneet Agarwal; Mark D Fleming; David A Williams
Journal:  Am J Hematol       Date:  2021-11-03       Impact factor: 10.047

6.  Sept6 is required for ciliogenesis in Kupffer's vesicle, the pronephros, and the neural tube during early embryonic development.

Authors:  Gang Zhai; Qilin Gu; Jiangyan He; Qiyong Lou; Xiaowen Chen; Xia Jin; Erfei Bi; Zhan Yin
Journal:  Mol Cell Biol       Date:  2014-01-27       Impact factor: 4.272

Review 7.  Topoisomerase II and leukemia.

Authors:  Maryjean Pendleton; R Hunter Lindsey; Carolyn A Felix; David Grimwade; Neil Osheroff
Journal:  Ann N Y Acad Sci       Date:  2014-02-03       Impact factor: 5.691

Review 8.  DNA topoisomerase II, genotoxicity, and cancer.

Authors:  A Kathleen McClendon; Neil Osheroff
Journal:  Mutat Res       Date:  2007-07-03       Impact factor: 2.433

9.  Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.

Authors:  Darrell C Bessette; Erik Tilch; Tatjana Seidens; Michael C J Quinn; Adrian P Wiegmans; Wei Shi; Sibylle Cocciardi; Amy McCart-Reed; Jodi M Saunus; Peter T Simpson; Sean M Grimmond; Sunil R Lakhani; Kum Kum Khanna; Nic Waddell; Fares Al-Ejeh; Georgia Chenevix-Trench
Journal:  PLoS One       Date:  2015-05-13       Impact factor: 3.240

10.  Pediatric M5 acute myeloid leukemia with MLL-SEPT6 fusion and a favorable outcome.

Authors:  Alain Chebly; Claudia Djambas Khayat; Tony Yammine; Rima Korban; Warde Semaan; Jessica Bou Zeid; Chantal Farra
Journal:  Leuk Res Rep       Date:  2021-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.